Abbott will sell its core laboratory diagnostics business included in the Abbott Diagnostics Division and Abbott Point of Care to GE for $8 billion in cash. Abbott’s Molecular Diagnostics and Diabetes Care businesses will remain part of Abbott. Abbott has made several acquisitions during the last few years as part of its strategy to strengthen the mix of its medical and pharmaceutical portfolio toward technology-driven businesses in emerging therapeutic areas. These include: Knoll Pha...